Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  United Therapeutics Corporation    UTHR

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

United Therapeutics Corporation : Warner Chilcott, Dynavax Technologies, Isis Pharma, United Therapeutics, and Pharmacyclics Under StockCall's Microscope

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/13/2013 | 01:05pm CET

LONDON, March 13, 2013 /PRNewswire/ --

The healthcare industry is adapting to the changing market dynamics. One of the biggest trends in the industry has been President Obama's comprehensive healthcare reform, Affordable Care Act (ACA). While ACA poses significant challenges to drug manufacturers such as Warner Chilcott Plc (NASDAQ: WCRX), Dynavax Technologies Corp. (NASDAQ: DVAX), ISIS Pharmaceuticals Inc. (NASDAQ: ISIS), United Therapeutics Corp. (NASDAQ: UTHR), and Pharmacyclics Inc. (NASDAQ: PCYC), another challenge for drug manufacturers has been increasing competition from generics following the expiration of patents on several blockbuster drugs in recent years. On Tuesday, healthcare stocks ended on a mixed note as the broad market struggled after a week-long rally. StockCall has released full comprehensive research on WCRX, DVAX, ISIS, UTHR, and PCYC and these free technical analyses can be downloaded by signing up at

http://www.stockcall.com/technicalanalysis

Shares of Warner Chilcott Plc fell sharply in Tuesday's trading session. The stock closed 1.10% lower at $13.46 on volume of 3.58 million. Despite the sharp decline yesterday, the stock is still up more than 1% in the last three sessions. Even as the healthcare industry faces challenges, Warner Chilcott's shares have performed well this year, gaining nearly 12%, compared to a gain of nearly 9% for the S&P 500. The stock is currently facing stiff resistance at around $13.75. Free technical analysis on WCRX available by signing up at

http://www.StockCall.com/WCRX031313.pdf

Shares of Dynavax Technologies Corporation saw a huge rally in Tuesday's trading session even as the broad market struggled. The stock ended the day 9.23% higher at $2.13 on volume of 3.29 million yesterday. In spite of Tuesday's rally, Dynavax's shares have fallen more than 25% this year. The stock broke through $2 resistance level yesterday, which is a bullish signal. The upbeat trend is further confirmed by the stock's MACD chart. Register today and access the free research on DVAX at

http://www.StockCall.com/DVAX031313.pdf

Shares of ISIS Pharmaceuticals Inc. rose sharply in Tuesday's session. The stock closed 1.36% higher at $17.94 on volume of 1.21 million. ISIS Pharmaceuticals shares have seen a series of highs in the last few trading sessions, which is a strong bullish signal. The stock has also broken through $15 resistance level. The optimistic trend is further confirmed by recent volume activity and the stock's MACD chart. The free report on ISIS can be downloaded by signing up now at

http://www.StockCall.com/ISIS031313.pdf

Shares of United Therapeutics Corp. posted modest gains in Tuesday's trading session. The stock closed 0.64% higher at $62.49 on above average volume of 967,367. Yesterday, United Therapeutics' shares reached a 52-week high of $62.61. The stock has had an excellent run in 2013, gaining nearly 17%. The drug maker's shares have seen a series of highs in the last one month, which is a strong bullish signal. The positive trend is further confirmed by recent volume activity. Free report on UTHR can be accessed by registering at

http://www.StockCall.com/UTHR031313.pdf

Shares of Pharmacyclics Inc. fell sharply in Tuesday's trading session. The stock closed 1.31% lower at $90.96 on above average volume of 897,740. Pharmacyclics' shares are currently trading close to their 52-week high of $95.85. The stock has fallen more than 3.70% in the last three trading sessions. Register with StockCall and download the research on PCYC for free at

http://www.StockCall.com/PCYC031313.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com

SOURCE StockCall.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on UNITED THERAPEUTICS CORPOR
11/10 UNITED THERAPEUTICS CORPORATION (NAS : UTHR) Investor Investigation over Potenti..
11/01 UNITED THERAPEUTICS CORPORATION : Purcell Julie & Lefkowitz LLP Is Investigating..
10/31 UNITED THERAPEUTICS CORPORATION : Levi & Korsinsky, LLP Announces an Investigati..
10/31 Purcell Julie & Lefkowitz LLP Is Investigating United Therapeutics Corporatio..
10/30 5 TOP NASDAQ BIOTECH STOCKS : Alexion Pharmaceuticals Leads
10/27 UNITED THERAPEUTICS : beats 3Q profit forecasts
10/27 UNITED THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
10/27 UNITED THERAPEUTICS CORP : Results of Operations and Financial Condition (form 8..
10/27 UNITED THERAPEUTICS CORPORATION : Reports Third Quarter 2016 Financial Results
10/20 UNITED THERAPEUTICS CORPORATION : To Report Third Quarter 2016 Financial Results..
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
12/09 BACKTESTING 101, PART 4 : Frictional Costs, To Hedge Or Not To Hedge, And Benchm..
12/09 VALUATION DASHBOARD : Healthcare - Update
12/05 28 Stocks For December 2016
12/01 GREENBLATT WIZARDRY : A Quantitative Look At The Magic Formula
11/29 Barclays softens views on five biopharma firms